Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Miriam T. Jacobs, Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Julio C. Chávez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
Topics & Concepts
MedicineLymphomaChimeric antigen receptorInternal medicineCytokine release syndromePopulationCD19CohortOncologyAntigenGastroenterologyImmunologyImmunotherapyCancerEnvironmental healthCAR-T cell therapy researchLymphoma Diagnosis and TreatmentImmune Cell Function and Interaction